Patents by Inventor Kare Engkilde

Kare Engkilde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MESENCHYMAL STEM CELLS FOR USE IN INCREASING EX-VIVO ORGAN LIFE
    Publication number: 20240164369
    Abstract: The present invention relates to the field of mesenchymal stem cells and their use in ex-vivo organ preservation.
    Type: Application
    Filed: March 18, 2022
    Publication date: May 23, 2024
    Inventors: Kåre Engkilde, Jan Talts, Sandra Lindstedt Ingemansson
  • PROCESSES AND APPARATUSES FOR OBTAINING AMNIOTIC MESENCHYMAL STEM CELLS FROM AMNIOTIC FLUID AND CELLS DERIVED THEREOF
    Publication number: 20220372444
    Abstract: Methods for purifying, culturing and selecting mesenchymal stem cell (MSC) subpopulations with neonatal quality and adult tissue specificity that are for use in production of advanced therapeutic medicinal products.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 24, 2022
    Inventors: Jan Talts, Niels-Bjarne Woods, Kåre Engkilde, Marcus Larsson
  • Use of term amniotic fluid cells for the treatment of acute and chronic respiratory diseases
    Patent number: 11446334
    Abstract: Methods for purifying, culturing and selecting mesenchymal stem cell (MSC) subpopulations with neonatal quality and adult tissue specificity are for in production of advanced therapeutic medicinal products. In certain examples, term amniotic fluid derived cells having characteristics of lung cells can be isolated. In some the term amniotic fluid derived cells having characteristics of lung cells can be used in the treatment of acute and chronic respiratory diseases.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: September 20, 2022
    Assignee: AMNIOTICS AB
    Inventors: Jan Talts, Niels-Bjarne Woods, Kare Engkilde, Marcus Larsson
  • IMMUNOMODULATION BY AMNIOTIC FLUID MESENCHYMAL STEM CELLS
    Publication number: 20220145250
    Abstract: Methods of reducing T cell activation including co-culturing with T cells, term amniotic fluid mesenchymal stem cells (TAF-MSCs) isolated from term human amniotic fluid. Other aspects relate to methods of inhibiting macrophage polarization toward the M1 pro-inflammatory phenotype including co-culturing with macrophages TAF-MSCs isolated from term human amniotic fluid. Other aspects relate to methods of inhibiting cytokine secretion from activated Peripheral Blood Mononuclear Cell (PBMC) including co-culturing with the PBMC tissue-typed TAF-MSCs isolated from human amniotic fluid. Other aspects relate to methods of differentiating TAF-MSC including: obtaining TAF-MSC cells from term amniotic fluid, plating the TAF-MSC cells in limiting dilution to obtain expanded colonies from single cells, and transferring the cells to a differentiation media that contains one or more factor to differentiate the TAF-MSC cells.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Jan Talts, Kåre Engkilde
  • USE OF TERM AMNIOTIC FLUID CELLS FOR THE TREATMENT OF ACUTE AND CHRONIC RESPIRATORY DISEASES
    Publication number: 20220118023
    Abstract: Methods for purifying, culturing and selecting mesenchymal stem cell (MSC) subpopulations with neonatal quality and adult tissue specificity are for in production of advanced therapeutic medicinal products. In certain examples, term amniotic fluid derived cells having characteristics of lung cells can be isolated. In some the term amniotic fluid derived cells having characteristics of lung cells can be used in the treatment of acute and chronic respiratory diseases.
    Type: Application
    Filed: December 30, 2021
    Publication date: April 21, 2022
    Inventors: Jan Talts, Nils-Bjarne Woods, Kare Engkilde, Marcus Larsson